Advertisement

Annals of Surgical Oncology

, Volume 26, Issue 10, pp 3368–3373 | Cite as

Intraoperative Ketorolac Use Does Not Increase the Risk of Bleeding in Breast Surgery

  • Kristin E. RojasEmail author
  • Thais A. Fortes
  • Peter Flom
  • Donna-Marie Manasseh
  • Charusheela Andaz
  • Patrick Borgen
Breast Oncology

Abstract

Background

The use of nonsteroidal anti-inflammatory drugs is an effective adjunct in managing perioperative pain. We sought to determine if the use of intraoperative ketorolac as part of a multimodal ERAS protocol increased the risk of bleeding complications in breast surgery.

Methods

A subset analysis of a prospective cohort study including patients undergoing lumpectomy and mastectomy compared two groups: those who received intraoperative ketorolac and those who did not. Bleeding complications were compared using Fisher’s exact test or t test, and analyzed with respect to surgical modality. Patients undergoing immediate reconstruction were excluded.

Results

Seven hundred and fifty-eight breast surgeries were performed in a 13-month period: 157 lumpectomy patients and 57 mastectomy patients met inclusion criteria between July 2017 and August 2018. Two hundred and fourteen patients were included in the analysis: 115 received ketorolac and 99 did not. The two groups were similar with regards to sex, age, race, tobacco use, and comorbidities. When analyzed together, there was no difference in bleeding complications between the group that received intraoperative ketorolac and those who did not (2% vs. 2.6%, p = 1.00). No hematomas occurred in the lumpectomy patients, and three occurred in mastectomy patients: one of which received ketorolac, and two did not (5.9% vs. 5.0%, p = 0.575). The rates of seroma, infection, or dehiscence were not significantly different between the two groups, regardless of surgical modality.

Conclusions

The use of intraoperative ketorolac is a useful adjunct in perioperative pain management in breast surgery and does not increase the risk of bleeding.

Notes

Acknowledgment

The authors acknowledge the Maimonides Medical Center anesthesiologists and perioperative staff, residents in the Departments of Surgery and Anesthesiology, pharmacists, and the administrative staff of the Brooklyn Breast Center of Maimonides Medical Center. They especially thank Johanna Yu, BSN, RN, Mohamad Hashim MD, Carin Zelkowitz PA-C, Jeffey Jacobs PA-C, and Mary-Ann Myrthil PA-C, whose cooperation and flexibility in implementing and promoting the ERAS protocol was not only beneficial to our study but to our patients.

Disclosure

Dr. P. Borgen and Dr. K. Rojas have received speaker’s honoraria from Pacira Pharmaceuticals, Inc. All other authors report no relevant commercial, financial, consultant, or institutional conflict of interest.

References

  1. 1.
    Nimmo SM, Foo ITH, Paterson HM. Enhanced recovery after surgery: pain management. J Surg Oncol. 2017;116:583–91.CrossRefGoogle Scholar
  2. 2.
    Rojas K, Manasseh DM, Flom PL, Agbroko S, Bilbro N, Andaz C, Borgen PI. A pilot study of a breast surgery Enhanced Recovery After Surgery (ERAS) protocol to eliminate narcotic prescription at discharge. Breast Cancer Res Treat. 2018;171(3):621–6.CrossRefGoogle Scholar
  3. 3.
    Gobbe RM, Hoang HL, Kachniarz B, Orgill DP. Ketorolac does not increase perioperative bleeding: a meta-analysis of randomized controlled trials. Plast Reconstr Surg. 2014;133(3):741–55.CrossRefGoogle Scholar
  4. 4.
    Duttchen KM, Lo A, Walker A, McLuckie D, De Guzman C, Roman-Smith H, Davis M. Intraoperative ketorolac dose of 15 mg versus the standard 30 mg on early postoperative pain after spine surgery: a randomized, blinded, non-inferiority trial. J Clin Anesth. 2017;41:11–5.CrossRefGoogle Scholar
  5. 5.
    Motov S, Yasavolian M, Likourezos A, et al. Comparison of intravenous ketorolac at three single-dose regimens for treating acute pain in the emergency department: a randomized controlled trial. Ann Emerg Med. 2017;70(2):177–84.CrossRefGoogle Scholar
  6. 6.
    Liang X, Liu R, Chen C, Ji F, Li T. Opioid system modulates the immune function: a review. Transl Perioper Pain Med. 2016;1(1):5–13.Google Scholar
  7. 7.
    Afsharimani B, Cabot P, Parat MO. Morphine and tumor growth metastasis. Cancer Metastasis Rev. 2011;30(2):225–38.CrossRefGoogle Scholar
  8. 8.
    Gupta K, Kshirsagar S, Chang L, Schwartz R, Law PY, Yee D, Hebbel RP. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res. 2002;62(15):4491–8.Google Scholar
  9. 9.
    Nestler EJ, Hyman SE, Holtzman DM, Malenka RC. Molecular neuropharmacology: a foundation for clinical neuroscience, 2nd edn. New York: McGraw-Hill Medical, 2009.Google Scholar
  10. 10.
    Cummings KC, Xu F, Cummings LC, Cooper GS. A comparison of epidural analgesia and traditional pain management effects on survival and cancer recurrence after colectomy: a population-based study. Anesthesiology. 2012;116(4):797–806.CrossRefGoogle Scholar
  11. 11.
    Cata JP, Keerty V, Keerty D, et al. A retrospective analysis of the effect of intraoperative opioid dose on cancer recurrence after non-small cell lung cancer resection. Cancer Med. 2014;3:900–8.CrossRefGoogle Scholar
  12. 12.
    Jiang W, Wang L, Zhang J, et al. Effects of postoperative non-steroidal anti-inflammatory drugs on long-term survival and recurrence of patients with non-small cell lung cancer. Medicine (Baltimore). 2018;97(39):e12442.CrossRefGoogle Scholar
  13. 13.
    Forget P, Vandenhende J, Berliere M, Machiels JP, Nussbaum B, Legrand C, De Kock M. Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis. Anesth Analg. 2010;110(6):1630–5.CrossRefGoogle Scholar
  14. 14.
    Forget P, Bentin C, Machiels JP, Berliere M, Coulie PG, De Kock M. Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery. Br J Anesth. 2014;113:i82–7.CrossRefGoogle Scholar
  15. 15.
    Retsky M, Demicheli R, Hrushesky W, et al. Reduction of breast cancer relapses with perioperative non-steroidal anti-inflammatory drugs: new findings and review. Curr Med Chem. 2013;20(33):4163–76.CrossRefGoogle Scholar
  16. 16.
    Zhao X, Xu Z, Li H. NSAIDs Use and reduced metastasis in cancer patients: results from a meta-analysis. Sci Rep. 2017;7(1):1875.CrossRefGoogle Scholar
  17. 17.
    Walter ND, Rice PL, Redente EF. Wound healing after trauma may predispose to lung cancer metastasis: review of potential mechanisms. Am J Respir Cell Mol Biol. 2011;44(5):591–6.CrossRefGoogle Scholar
  18. 18.
    Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998; 93(5):705–16.CrossRefGoogle Scholar
  19. 19.
    Baek SJ, Okazaki R, Lee SH, et al. Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia. Gastroenterology. 2006;131:1553–60.CrossRefGoogle Scholar
  20. 20.
    Cekanova M, Lee SH, Donnell RL, Sukhthankar M, Eling TE, Fischer SM, Baek SJ. Nonsteroidal anti-inflammatory drug-activated gene-1 expression inhibits urethane-induced pulmonary tumorigenesis in transgenic mice. Cancer Prev Res. 2009;2:450–8.CrossRefGoogle Scholar
  21. 21.
    Sharma S, Chang DW, Koutz C, Evans GR, Robb GL, Langstein HN, Kroll SS. Incidence of hematoma associated with ketorolac after TRAM flap breast reconstruction. Plast Reconstr Surg. 2001;107(2):352–5.CrossRefGoogle Scholar
  22. 22.
    Batdorf NJ, Lemaine V, Lovely JK, et al. Enhanced recovery after surgery in microvascular breast reconstruction. J Plast Reconstr Aesthet Surg. 2015;68(3):395–402.CrossRefGoogle Scholar
  23. 23.
    Mikhaylov Y, Weinstein B, Schrannk TP, Swartz JD, Ulm JP, Armstrong MB, Delaney KO. Ketorolac and hematoma incidence in postmastectomy implant-based breast reconstruction. Ann Plast Surg. 2018; 80(5):472–4.Google Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  1. 1.Maimonides Medical Center Department of SurgeryBrooklynUSA
  2. 2.Peter Flom ConsultingNew YorkUSA

Personalised recommendations